GT Medical Technologies announced today that new data on the company’s innovative GammaTile therapy for patients with operable brain tumours will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) annual scientific meeting (29 April–2 May; Philadelphia, USA).
The abstract will provide the first report of “impressive” clinical outcomes in recurrent glioblastoma patients treated with the US Food and Drug Administration (FDA)-cleared technology—including a median local control of 81% at 12 months and median overall survival reaching 37 months in O6-methylguanine-DNA methyltransferase (MGMT) methylated patients. The safety profile was comparable to patients undergoing repeat surgery without GammaTile treatment, as per a GT press release.
GammaTile therapy is a bioresorbable 3D-collagen tile embedded with Cesium-131 sources that is implanted in the last five minutes of brain tumour removal surgery. The sustained, controlled and therapeutic dose of radiation immediately begins targeting remaining tumour cells, sparing healthy tissue.
“There is no established standard of care today for patients with recurrent glioblastoma. This abstract, along with other studies and clinical publications, supports that GammaTile therapy should be considered for all patients with operable recurrent glioblastomas,” said Matthew Likens, president and CEO of GT. “Patients receiving GammaTile therapy have the benefit of prolonged survival without sacrificing quality of life. Our company purpose is to improve the lives of patients with brain tumours, and Dr Chen’s early clinical experience at University of Minnesota advances this purpose.”
The abstract, titled “GammaTile brachytherapy in the treatment of recurrent glioblastomas”, earned lead author Clark Chen (University of Minnesota Medical School, Minnesota, USA) the prestigious BrainLab Neurosurgery Award—which is set to be presented at the annual meetings of the AANS and the Congress of Neurological Surgeons (CNS; 8–12 October 2022, San Francisco, USA), and is given to a neurosurgeon with a high-scoring abstract relating to central nervous system tumours.
“The treatment of recurrent glioblastoma remains a major challenge in our field, without consensus for a standard of care,” said Chen. “Our published results suggest clinical benefit from GammaTile treatment and warrant consideration in this setting, especially given the highly favourable safety profile. Recapitulation of our results in a larger, multi-institution cohort has the potential to redefine the standard of care for recurrent glioblastoma patients.”
The abstract will be presented on Monday 2 May in the AANS 2022 tumour abstract session.
